在进行中的临床试验中新增治疗臂的设计方法
本文针对两项平行组试验进行期间新增一个实验治疗臂的场景,提出一种适应性设计,在新臂加入时调整样本量,以强控制族错误率(FWER)并维持各治疗与对照比较的边际把握度至原研究水平。研究还探讨了以提升总体把握度为目标的最优分配。结论提示:若需在FWER层面控制,新增臂需增加样本量;在某些设计特征下,为每个实验治疗单独开展试验可能更节省患者。
要点
- 新增治疗臂并需控制FWER时,须增加样本量以维持各比较的边际把握度。
- 新增臂后采用最优分配可提升总体把握度,优于继续等比例分配。
- 若各实验治疗可分开试验且无需在同一试验内控制FWER,单独试验可能更省患者。
核心结论
- 新增治疗臂并需强控制FWER时,需增加样本量以维持各治疗与对照比较的边际把握度。
- 新增臂后采用最优分配可提升总体把握度,优于继续对所有治疗臂等比例分配。
- 当FWER控制并非必须在同一试验内实现时,视设计特征,为每个实验治疗单独开展试验可能在所需患者数上更优。
研究设计与样本
- 提出一种适应性设计,在新治疗臂加入时调整样本量,以强控制FWER并维持边际把握度。
- 考虑两项平行组试验进行期间新增一个实验治疗臂,新臂仅与同期随机对照比较。
- 探索以提升总体把握度为目标的最优分配,总体把握度定义为检出所有优于对照的治疗的概率。
主要发现
- 新增治疗臂并需在FWER层面控制时,维持各 pairwise 比较的边际把握度需要增加样本量。
- 采用最优分配而非继续等比例分配,可在新增臂后提升总体把握度。
- 是否单独开展试验更省患者取决于设计特征。
临床怎么用
- 在设计中期新增治疗臂时,应预先考虑FWER强控制与样本量调整策略。
- 新增臂后宜评估最优分配以提升总体把握度,而非默认等比例分配。
- 若各实验治疗无需在同一试验内共享FWER控制,可比较单独试验与单试验新增臂的患者数需求。
局限性
- 摘要未报告具体样本量、检验效能数值或模拟参数。
- 结论基于方法学设计探讨,未提供实证试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For many disease areas, there are often treatments in different stages of the development process. We consider the design of a two-arm parallel group trial where it is planned to add a new experimental treatment arm during the trial. This could potentially save money, patients, time and resources; however, the addition of a treatment arm creates a multiple comparison problem. Current practice in trials when a new treatment arm has been added is to compare the new treatment only to controls randomised concurrently, and this is the setting we consider here. Furthermore, for standard multi-arm trials, optimal allocation randomises a larger number of patients to the control arm than to each experimental treatment arm. METHODS: In this paper we propose an adaptive design, the aim of which is to adapt the sample size of the trial when the new treatment arm is added to control the family-wise error rate (FWER) in the strong sense, whilst maintaining the marginal power of each treatment-to-control comparison at the level of the original study. We explore optimal allocation for designs where a treatment arm is added with the aim of increasing the overall power of the study, where we define the overall power to be the probability of detecting all treatments that are better than the control. RESULTS AND CONCLUSIONS: An increase in sample size is required to maintain the marginal power for each pairwise comparison when adding a treatment arm if control of the FWER is required at the level of the type I error in the original study. When control of the FWER is required in a single trial which adds an additional experimental treatment arm, but control of the FWER is not required in separate trials, depending on the design characteristics, it may be better to run a separate trial for each experimental treatment, in terms of the number of patients required. An increase in overall power can be achieved when optimal allocation is used once a treatment arm has been added to the trial, rather than continuing with equal allocation to all treatment arms.
引用
- Bennett M, Mander AP. Designs for adding a treatment arm to an ongoing clinical trial. Trials. 2020. PMID: 32143729. doi:10.1186/s13063-020-4073-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。